Published June 2019
| Version v1
Journal article
Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer
- 1. Department of Radiation Medicine, Zucker School of Medicine, Hempstead, New York (United States)
Description
This study presents a prospective phase 1, institutional review board–approved dose-escalated stereotactic body radiation therapy trial for prostate cancer (CaP) to assess the impact of dose level on quality of life, toxicity, and clinical outcomes.
Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2019.01.092;
- PII
- S036030161930183X;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 104
- Journal Issue
- 2
- Journal Page Range
- p. 334-342
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55057205
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- HEALTH HAZARDS; NEOPLASMS; PATIENTS; PROSTATE; QUALITY OF LIFE; RADIATION DOSES; RADIOTHERAPY; REVIEWS; TOXICITY
- Descriptors DEC
- BODY; DISEASES; DOCUMENT TYPES; DOSES; GLANDS; HAZARDS; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2019 Elsevier Inc. All rights reserved.